Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244952 | 0.85 | RBP4 (0.59) | ASIC3RBP4ALDH1A1L3MBTL1HTT | |
| SCHEMBL382564 | 0.85 | NOTUM (0.51) | PDE3BPDE3ARBP4HSD11B1 | |
| SCHEMBL12017807 | 0.82 | ADRB2 (0.55) | ASIC3PDE3BPDE3APIM1CDK4 | |
| SCHEMBL31744938 | 0.81 | HSD11B1 (0.48) | RBP4HSD11B1ALDH1A1MTORHTT | |
| SCHEMBL24681546 | 0.81 | POLB (0.59) | ASIC3PDE3BPDE3APIM1CDK4 | |
| SCHEMBL29623590 | 0.81 | NOTUM (0.54) | PDE3BPDE3AHSD11B1ALDH1A1MTOR | |
| SCHEMBL29959068 | 0.81 | MAPT (0.59) | ASIC3PDE3BPDE3APIM1CDK4 | |
| SCHEMBL24309870 | 0.81 | ASIC3 (0.52) | ASIC3PDE3BPDE3APIM1CDK4 | |
| SCHEMBL17115170 | 0.81 | NCF1 (0.48) | ASIC3ALDH1A1HTTMAPT | |
| SCHEMBL17102319 | 0.81 | NOTUM (0.54) | PDE3BPDE3AHSD11B1ALDH1A1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| WO-2015140051-A1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140054-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ASIC3 4537/4885PDE3B 2654/4885PDE3A 3569/4885 |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, IRAK1 | ASIC3 4537/4885PDE3B 2141/4885PDE3A 3145/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | ASIC3 4537/4885PDE3B 2654/4885PDE3A 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.